X
Access Company Profiles

Get business overview, business operations details specific to this market, products and services, latest developments and more...

Business Email

Select Companies

 

Europe Ovarian Cancer Diagnostics and Therapeutics Companies

This report lists the top Europe Ovarian Cancer Diagnostics and Therapeutics companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Europe Ovarian Cancer Diagnostics and Therapeutics industry.

Europe Ovarian Cancer Diagnostics and Therapeutics Top Companies

  1. F. Hoffmann-La Roche Ltd

  2. Siemens Healthineers AG

  3. Johnson and Johnson (Janssen Pharmaceuticals)

  4. Eli Lilly and Company

  5. GlaxoSmithKline PLC

*Disclaimer: Top companies sorted in no particular order

 Europe Ovarian Cancer Diagnostics and Therapeutics Market Major Players

Europe Ovarian Cancer Diagnostics and Therapeutics Market Concentration

Europe Ovarian Cancer Diagnostics and Therapeutics Market Concentration

Europe Ovarian Cancer Diagnostics and Therapeutics Company List

                      • Amneal Pharmaceuticals LLC

                      • AstraZeneca PLC

                      • Boehringer Ingelheim International GmbH

                      • Bristol Myers Squibb Company

                      • Eli Lilly and Company

                      • F. Hoffman-La Roche Ltd

                      • GlaxoSmithKline PLC

                      • Johnson and Johnson (Janssen Pharmaceuticals)

                      • Pfizer Inc.

                      • Siemens Healthineers AG

                      • Ovation Diagnostics

                      • INEX Innovate


                  Specific to Europe Ovarian Cancer Diagnostics and Therapeutics Market
                  Need More Details On Market Players And Competitors?
                  Download Sample

                  Europe Ovarian Cancer Diagnostics and Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)